Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Microarray Analyses of mRNA and lncRNA in TAMs isolated from breast tumor of PyMT mice with or without chemotherapy

ABSTRACT: Microarray Analyses of mRNA and lncRNA in TAMs isolated from breast tumor of PyMT mice with or without chemotherapy

PROVIDER: PRJNA555835 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Microarray Analyses of mRNA and lncRNA in TAMs isolated from breast tumor of PyMT mice with or without chemotherapy

Project description:Chemotherapies have been shown to enhance anti-tumor immunity, but whether chemotherapies affect tumor-associated macrophages (TAMs) is still uclear. We found TAMs is different with or without chemotherapy by comparing RNA profile of TAMs with or without chemotherapy.

2021-02-16 | GSE134601 | GEO

Microarray Analyses of lncRNA and mRNA in TAMs from breast cancer patient before or after chemotherapy

Project description:Chemotherapies have been shown to enhance anti-tumor immunity, but whether chemotherapies affect tumor-associated macrophages (TAMs) is still uclear. We found TAMs is different before and after chemotherapy by comparing RNA profile of TAMs before and after chemotherapy.

2021-02-16 | GSE134600 | GEO

Expression data from PyMT;Lys Cre:E2f3 f/f TAMs

Project description:To understand the underlying cause for reduced lung metastasis, we compared global gene expression profiles of F4/80+ FACS sorted tumor-associated macrophages (TAMs) PyMT;E2f3 f/f (control) and PyMT;Lys Cre:E2f3 f/f (experimental) mice. We compared gene expression profile between TAMs isolated from mammary tumors of PyMT;E2f3 f/f and PyMT;Lys Cre:E2f3 f/f mice

2017-04-04 | GSE67081 | GEO

Chemotherapy-polarized macrophages from breast tumor of PyMT mice

Project description:Chemotherapies have been shown to enhance anti-tumor immunity, but whether chemotherapies affect tumor-associated macrophages (TAMs) is still unclear. We found TAMs is different before and after chemotherapy by comparing proteomic profiles of TAMs before and after chemotherapy.

2021-02-16 | PXD022674 | Pride

Characterization of the Chemotherapy-treated PyMT Matrisome

Project description:Cytotoxic chemotherapy is used to treat many thousands of patients across many cancer types annually. Recent studies have demonstrated that chemotherapy causes systemic response that can be exploited to promote cancer cell survival and dissemination, termed “chemotherapy-induced metastasis. However, there have been no studies investigating how chemotherapy alters the extracellular matrix of breast tumors, or if those changes might help to support metastatic dissemination. Here, we report the first characterization of the chemotherapy-treated breast cancer matrisome using the MMTV-PyMT transgenic mouse model of breast cancer. We identify distinct changes induced by different cytotoxic chemotherapies. In particular, we identify collagen IV as significantly associated with taxane-based chemotherapy treatment. Biological validation confirmed collagen IV as chemotherapy-associated and identified collagen IV-driven Src and FAK signaling as important mediators of invasion in the post-chemotherapy tumor microenvironment.

2022-03-14 | PXD032002 | Pride

Gene expression profile at single nucleus level for tumor associated macrophage (TAMs) nuclei sorted from tumor of control-PyMT and S100a8-creRosa26-LSL-MYCPyMT (MYC-PyMT) mice treated with low protein diet

Project description:Nuclei of TAMs were sorted for single nucleus RNA sequencing from control-PyMT and MYC-PyMT tumor treated with low protein diet, and compare their transcriptome differences.

2023-04-24 | GSE230245 | GEO

Characterization of Chemotherapy-treated PyMT Liver Matrisome

Project description:Metastasis accounts for 90% of cancer-related deaths, yet the mechanisms by which cancer cells colonize secondary organs remain poorly understood. For breast cancer patients, metastasis to the liver is associated with poor prognosis and a median survival of 6 months. Standard of care is chemotherapy, but recurrence occurs in 30% of patients. Systemic chemotherapy has been shown to induce hepatotoxicity and fibrosis, but how chemotherapy impacts the composition of the liver extracellular matrix (ECM) remains unknown. Individual ECM proteins drive tumor cell proliferation and invasion, features that are essential for metastatic outgrowth in the liver. Here, we characterize the liver ECM of tumor-bearing mice treated with and without chemotherapy using the MMTV-PyMT transgenic model of breast cancer. We identify distinct drug-specific changes induced by commonly used cytotoxic chemotherapies. We identify Collagen V as an ECM protein that is more abundant in livers isolated from paclitaxel-treated mice and identify mechanisms of Collagen V driven invasion via ECM organization and signaling through α1β1 integrins.

2022-10-05 | PXD036736 | Pride

Microarray Analyses of lncRNA and mRNA in TAMs from breast cancer patient before or after chemotherapy

Project description:Microarray Analyses of lncRNA and mRNA in TAMs from breast cancer patient before or after chemotherapy

| PRJNA555834 | ENA

Chemotherapy-polarized macrophages from human breast cancer

2021-02-16 | PXD022673 | Pride

Synergism of chemotherapy and PD-1 immune checkpoint blockade in the PyMT mammary carcinoma mouse model

Project description:We studied the impact of a combination of chemotherapy and PD-1 immune checkpoint blockade on tumor progression in the PyMT mammary carcinoma mouse model compared to each treatment as monotherapy. To gain insight into the reasons underlying improved efficacy of combined chemoimmunotherapy, whole transcriptome profiling of tumors of mice receiving either a control antibody, anti-PD-1 antibody, doxorubicin chemotherapy + a control antibody or doxorubicin chemotherapy + anti-PD-1 antibody was performed via next generation mRNA sequencing, in triplicates, on a NextSeq 550 high-throughput bench top sequencer.

2020-08-27 | GSE149479 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data